The PI3K/mTOR inhibitor Gedatolisib eliminates dormant breast cancer cells in organotypic culture, but fails to prevent metastasis in preclinical settings
Dormant, disseminated tumor cells (DTCs) are thought to be the source of breast cancer metastases several years or even decades after initial treatment. To date, a selective therapy that leads to their elimination has not been discovered. While dormant DTCs resist chemotherapy, evidence suggests tha...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2022-01-01
|
| Series: | Molecular Oncology |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/1878-0261.13031 |
| _version_ | 1819283697261608960 |
|---|---|
| author | Ryann E. Shor Jinxiang Dai Sun‐Young Lee Laura Pisarsky Irina Matei Serena Lucotti David Lyden Mina J. Bissell Cyrus M. Ghajar |
| author_facet | Ryann E. Shor Jinxiang Dai Sun‐Young Lee Laura Pisarsky Irina Matei Serena Lucotti David Lyden Mina J. Bissell Cyrus M. Ghajar |
| author_sort | Ryann E. Shor |
| collection | DOAJ |
| description | Dormant, disseminated tumor cells (DTCs) are thought to be the source of breast cancer metastases several years or even decades after initial treatment. To date, a selective therapy that leads to their elimination has not been discovered. While dormant DTCs resist chemotherapy, evidence suggests that this resistance is driven not by their lack of proliferation, but by their engagement of the surrounding microenvironment, via integrin‐β1‐mediated interactions. Because integrin‐β1‐targeted agents have not been translated readily to the clinic, signaling nodes downstream of integrin‐β1 could serve as attractive therapeutic targets in order to sensitize dormant DTCs to therapy. By probing a number of kinases downstream of integrin‐β1, we determined that PI3K inhibition with either a tool compounds or a compound (PF‐05212384; aka Gedatolisib) in clinical trials robustly sensitizes quiescent breast tumor cells seeded in organotypic bone marrow cultures to chemotherapy. These results motivated the preclinical study of whether Gedatolisib—with or without genotoxic therapy—would reduce DTC burden and prevent metastases. Despite promising results in organotypic culture, Gedatolisib failed to reduce DTC burden or delay, reduce or prevent metastasis in murine models of either triple‐negative or estrogen receptor‐positive breast cancer dissemination and metastasis. This result held true whether analyzing Gedatolisib on its own (vs. vehicle‐treated animals) or in combination with dose‐dense doxorubicin and cyclophosphamide (vs. animals treated only with dose‐dense chemotherapies). These data suggest that PI3K is not the node downstream of integrin‐β1 that confers chemotherapeutic resistance to DTCs. More broadly, they cast doubt on the strategy to target PI3K in order to eliminate DTCs and prevent breast cancer metastasis. |
| first_indexed | 2024-12-24T01:35:36Z |
| format | Article |
| id | doaj.art-a3a3a49dc68740cfb9870a78fd1324e9 |
| institution | Directory Open Access Journal |
| issn | 1574-7891 1878-0261 |
| language | English |
| last_indexed | 2024-12-24T01:35:36Z |
| publishDate | 2022-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Molecular Oncology |
| spelling | doaj.art-a3a3a49dc68740cfb9870a78fd1324e92022-12-21T17:22:13ZengWileyMolecular Oncology1574-78911878-02612022-01-0116113014710.1002/1878-0261.13031The PI3K/mTOR inhibitor Gedatolisib eliminates dormant breast cancer cells in organotypic culture, but fails to prevent metastasis in preclinical settingsRyann E. Shor0Jinxiang Dai1Sun‐Young Lee2Laura Pisarsky3Irina Matei4Serena Lucotti5David Lyden6Mina J. Bissell7Cyrus M. Ghajar8Public Health Sciences Division/Translational Research Program Fred Hutchinson Cancer Research Center Seattle WA USAPublic Health Sciences Division/Translational Research Program Fred Hutchinson Cancer Research Center Seattle WA USABiological Systems and Engineering Division Lawrence Berkeley National Laboratory CA USAPublic Health Sciences Division/Translational Research Program Fred Hutchinson Cancer Research Center Seattle WA USAChildren’s Cancer and Blood Foundation Laboratories Department of Pediatrics, and Cell and Developmental Biology Drukier Institute for Children’s Health Meyer Cancer Center Weill Cornell Medicine New York NY USAChildren’s Cancer and Blood Foundation Laboratories Department of Pediatrics, and Cell and Developmental Biology Drukier Institute for Children’s Health Meyer Cancer Center Weill Cornell Medicine New York NY USAChildren’s Cancer and Blood Foundation Laboratories Department of Pediatrics, and Cell and Developmental Biology Drukier Institute for Children’s Health Meyer Cancer Center Weill Cornell Medicine New York NY USABiological Systems and Engineering Division Lawrence Berkeley National Laboratory CA USAPublic Health Sciences Division/Translational Research Program Fred Hutchinson Cancer Research Center Seattle WA USADormant, disseminated tumor cells (DTCs) are thought to be the source of breast cancer metastases several years or even decades after initial treatment. To date, a selective therapy that leads to their elimination has not been discovered. While dormant DTCs resist chemotherapy, evidence suggests that this resistance is driven not by their lack of proliferation, but by their engagement of the surrounding microenvironment, via integrin‐β1‐mediated interactions. Because integrin‐β1‐targeted agents have not been translated readily to the clinic, signaling nodes downstream of integrin‐β1 could serve as attractive therapeutic targets in order to sensitize dormant DTCs to therapy. By probing a number of kinases downstream of integrin‐β1, we determined that PI3K inhibition with either a tool compounds or a compound (PF‐05212384; aka Gedatolisib) in clinical trials robustly sensitizes quiescent breast tumor cells seeded in organotypic bone marrow cultures to chemotherapy. These results motivated the preclinical study of whether Gedatolisib—with or without genotoxic therapy—would reduce DTC burden and prevent metastases. Despite promising results in organotypic culture, Gedatolisib failed to reduce DTC burden or delay, reduce or prevent metastasis in murine models of either triple‐negative or estrogen receptor‐positive breast cancer dissemination and metastasis. This result held true whether analyzing Gedatolisib on its own (vs. vehicle‐treated animals) or in combination with dose‐dense doxorubicin and cyclophosphamide (vs. animals treated only with dose‐dense chemotherapies). These data suggest that PI3K is not the node downstream of integrin‐β1 that confers chemotherapeutic resistance to DTCs. More broadly, they cast doubt on the strategy to target PI3K in order to eliminate DTCs and prevent breast cancer metastasis.https://doi.org/10.1002/1878-0261.13031breast cancerdisseminated tumor cell dormancygedatolisibintegrin‐β1metastasisphosphatidylinositol 3‐kinase/PI3K |
| spellingShingle | Ryann E. Shor Jinxiang Dai Sun‐Young Lee Laura Pisarsky Irina Matei Serena Lucotti David Lyden Mina J. Bissell Cyrus M. Ghajar The PI3K/mTOR inhibitor Gedatolisib eliminates dormant breast cancer cells in organotypic culture, but fails to prevent metastasis in preclinical settings Molecular Oncology breast cancer disseminated tumor cell dormancy gedatolisib integrin‐β1 metastasis phosphatidylinositol 3‐kinase/PI3K |
| title | The PI3K/mTOR inhibitor Gedatolisib eliminates dormant breast cancer cells in organotypic culture, but fails to prevent metastasis in preclinical settings |
| title_full | The PI3K/mTOR inhibitor Gedatolisib eliminates dormant breast cancer cells in organotypic culture, but fails to prevent metastasis in preclinical settings |
| title_fullStr | The PI3K/mTOR inhibitor Gedatolisib eliminates dormant breast cancer cells in organotypic culture, but fails to prevent metastasis in preclinical settings |
| title_full_unstemmed | The PI3K/mTOR inhibitor Gedatolisib eliminates dormant breast cancer cells in organotypic culture, but fails to prevent metastasis in preclinical settings |
| title_short | The PI3K/mTOR inhibitor Gedatolisib eliminates dormant breast cancer cells in organotypic culture, but fails to prevent metastasis in preclinical settings |
| title_sort | pi3k mtor inhibitor gedatolisib eliminates dormant breast cancer cells in organotypic culture but fails to prevent metastasis in preclinical settings |
| topic | breast cancer disseminated tumor cell dormancy gedatolisib integrin‐β1 metastasis phosphatidylinositol 3‐kinase/PI3K |
| url | https://doi.org/10.1002/1878-0261.13031 |
| work_keys_str_mv | AT ryanneshor thepi3kmtorinhibitorgedatolisibeliminatesdormantbreastcancercellsinorganotypicculturebutfailstopreventmetastasisinpreclinicalsettings AT jinxiangdai thepi3kmtorinhibitorgedatolisibeliminatesdormantbreastcancercellsinorganotypicculturebutfailstopreventmetastasisinpreclinicalsettings AT sunyounglee thepi3kmtorinhibitorgedatolisibeliminatesdormantbreastcancercellsinorganotypicculturebutfailstopreventmetastasisinpreclinicalsettings AT laurapisarsky thepi3kmtorinhibitorgedatolisibeliminatesdormantbreastcancercellsinorganotypicculturebutfailstopreventmetastasisinpreclinicalsettings AT irinamatei thepi3kmtorinhibitorgedatolisibeliminatesdormantbreastcancercellsinorganotypicculturebutfailstopreventmetastasisinpreclinicalsettings AT serenalucotti thepi3kmtorinhibitorgedatolisibeliminatesdormantbreastcancercellsinorganotypicculturebutfailstopreventmetastasisinpreclinicalsettings AT davidlyden thepi3kmtorinhibitorgedatolisibeliminatesdormantbreastcancercellsinorganotypicculturebutfailstopreventmetastasisinpreclinicalsettings AT minajbissell thepi3kmtorinhibitorgedatolisibeliminatesdormantbreastcancercellsinorganotypicculturebutfailstopreventmetastasisinpreclinicalsettings AT cyrusmghajar thepi3kmtorinhibitorgedatolisibeliminatesdormantbreastcancercellsinorganotypicculturebutfailstopreventmetastasisinpreclinicalsettings AT ryanneshor pi3kmtorinhibitorgedatolisibeliminatesdormantbreastcancercellsinorganotypicculturebutfailstopreventmetastasisinpreclinicalsettings AT jinxiangdai pi3kmtorinhibitorgedatolisibeliminatesdormantbreastcancercellsinorganotypicculturebutfailstopreventmetastasisinpreclinicalsettings AT sunyounglee pi3kmtorinhibitorgedatolisibeliminatesdormantbreastcancercellsinorganotypicculturebutfailstopreventmetastasisinpreclinicalsettings AT laurapisarsky pi3kmtorinhibitorgedatolisibeliminatesdormantbreastcancercellsinorganotypicculturebutfailstopreventmetastasisinpreclinicalsettings AT irinamatei pi3kmtorinhibitorgedatolisibeliminatesdormantbreastcancercellsinorganotypicculturebutfailstopreventmetastasisinpreclinicalsettings AT serenalucotti pi3kmtorinhibitorgedatolisibeliminatesdormantbreastcancercellsinorganotypicculturebutfailstopreventmetastasisinpreclinicalsettings AT davidlyden pi3kmtorinhibitorgedatolisibeliminatesdormantbreastcancercellsinorganotypicculturebutfailstopreventmetastasisinpreclinicalsettings AT minajbissell pi3kmtorinhibitorgedatolisibeliminatesdormantbreastcancercellsinorganotypicculturebutfailstopreventmetastasisinpreclinicalsettings AT cyrusmghajar pi3kmtorinhibitorgedatolisibeliminatesdormantbreastcancercellsinorganotypicculturebutfailstopreventmetastasisinpreclinicalsettings |